Narrowing Valuation Differences on Investment Securities and Recognition of Impairment Losses
First written in FY2017-Q1. 18 of 36 entries say "Mitigated", first in FY2017-Q3. Latest entry: 2026-07-30.
The whole theme swung hardest in 2022: 10 of 55 companies on the "Worse" side.
8 other companies' latest entry also says "Mitigated".
- 2026-07-30MitigatedEarnings
「Valuation difference on other securities 6,900,887 7,248,913」
The valuation difference on other securities increased from ¥6,900 million at the end of the previous fiscal year to ¥7,248 million. - FY2026WorsenedAnnual report
「Investment securities valuation loss — ¥60.000 million」
An investment securities valuation loss of ¥60 million was recorded, whereas none was recorded in the previous year. Meanwhile, the valuation difference on other securities increased from ¥4,982 million to ¥6,901 million. - 2026-05-14ReframedEarnings
「Valuation difference on other securities 4,982,683 6,900,887」
The valuation difference on other securities increased, while a ¥60 million impairment loss on investment securities was also recorded in the fiscal year, reflecting a change in how valuation effects appeared. - FY2026-H1MitigatedAnnual report
「Valuation difference on other securities 4,982,683 5,984,927」
Other securities valuation difference increased from ¥4,982.683 million at the end of the previous fiscal year to ¥5,984.927 million. No investment securities valuation loss has been reported. - FY2025WorsenedAnnual report
「Valuation difference on other securities 5,492,889 4,982,683」
The valuation difference on other securities decreased from ¥5,492.889 million at the end of the previous fiscal year to ¥4,982.683 million. No impairment loss on investment securities was indicated. - FY2025-H1WorsenedAnnual report
「Valuation difference on other securities 5,492,889 4,869,770」
The valuation difference on other securities decreased from ¥5,492.889 million at the end of the previous fiscal year to ¥4,869.770 million. No impairment loss on investment securities was indicated. - FY2024MitigatedAnnual report
「Valuation difference on other securities 2,623,695 5,492,889」
The valuation difference on other securities increased substantially from the end of the previous fiscal year, and no impairment loss on investment securities was recorded. Valuation differences recovered further. - FY2024-Q3MitigatedAnnual report
「Valuation difference on other securities 2,623,695 4,464,311」
The valuation difference on other securities increased from ¥2,623.695 million at the end of the previous fiscal year to ¥4,464.311 million, and no impairment loss on investment securities was recorded. Valuation differences continued to recover. - FY2024-Q2MitigatedAnnual report
「Valuation difference on other securities 2,623,695 4,069,025」
The valuation difference on other securities increased from ¥2,623.695 million at the end of the previous fiscal year to ¥4,069.025 million. No impairment loss on investment securities was recorded, and the valuation difference recovered. - FY2024-Q1MitigatedAnnual report
「Valuation difference on other securities 2,623,695 3,203,582」
The valuation difference on other securities increased from ¥2,623.695 million at the end of the previous fiscal year to ¥3,203.582 million. No impairment loss on investment securities was recorded, and valuation differences continued to recover. - FY2023MitigatedAnnual report
「Valuation difference on other securities 1,878,834 2,623,695」
The valuation difference on other securities increased from ¥1,878.834 million at the end of the previous fiscal year to ¥2,623.695 million, indicating continued recovery in valuation differences. No impairment loss on investment securities was recorded in the current fiscal year. - FY2023-Q3MitigatedAnnual report
「Valuation difference on other securities 1,878,834 2,075,309」
The valuation difference on other securities increased from ¥1,878.834 million at the end of the previous fiscal year to ¥2,075.309 million. No impairment loss on investment securities was recorded during the cumulative third-quarter period, indicating a recovery in valuation differences. - FY2023-Q2ReframedAnnual report
「Valuation difference on other securities 1,878,834 1,728,412」
The valuation difference on other securities decreased from the end of the previous fiscal year. Meanwhile, the ¥1.250 million impairment loss on investment securities recorded in the same period of the previous year was not recorded during the cumulative second-quarter period of the current fiscal year. - FY2023-Q1ReframedAnnual report
「Valuation difference on other securities 1,878,834 1,700,384」
The valuation difference on other securities decreased from ¥1,878.834 million at the end of the previous fiscal year to ¥1,700.384 million. Meanwhile, the ¥1.248 million impairment loss on investment securities recorded in the same period of the previous year was not recorded in the current quarter, indicating a narrowing valuation difference alongside the disappearance of the valuation loss. - FY2022MitigatedAnnual report
「Valuation difference on other securities 1,793,731 1,878,834」
The valuation difference on other securities increased from ¥1,793.731 million at the end of the previous fiscal year to ¥1,878.834 million, and no impairment loss on investment securities was recorded in the current fiscal year. - FY2022-Q3ReframedAnnual report
「Valuation difference on other securities 1,793,731 1,687,740」
The valuation difference on other securities decreased from the end of the previous fiscal year, and the valuation difference on other securities for the cumulative third-quarter period of the current consolidated fiscal year was negative ¥109.980 million. Meanwhile, the current fiscal year's income statement does not indicate any impairment loss on investment securities. - FY2022-Q1WorsenedAnnual report
「Impairment loss on investment securities - 1,248」
An impairment loss on investment securities of ¥1.248 million, which was not recorded in the same period of the previous year, was recognized. In addition, the valuation difference on other securities decreased from ¥1,793.731 million at the end of the previous fiscal year to ¥1,641.776 million. - FY2021MitigatedAnnual report
「Impairment loss on investment securities 1,367,977 ―」
The impairment loss on investment securities decreased from ¥1,367.977 million in the previous fiscal year to none in the current fiscal year. In addition, the valuation difference on other securities increased from ¥755.290 million to ¥1,793.731 million. - FY2021-Q3MitigatedAnnual report
「Impairment loss on investment securities 227,976 -」
The impairment loss on investment securities decreased from ¥227.976 million in the same period of the previous year to none in the current quarter. In addition, the valuation difference on other securities increased from ¥755.290 million to ¥1,266.536 million. - FY2021-Q2MitigatedAnnual report
「Impairment loss on investment securities 256,813 1,317」
The impairment loss on investment securities decreased substantially from ¥256.813 million in the same period of the previous year to ¥1.317 million. In addition, the valuation difference on other securities increased from ¥755.290 million at the end of the previous fiscal year to ¥1,013.265 million. - FY2021-Q1MitigatedAnnual report
「Impairment loss on investment securities 233,724 -」
The impairment loss on investment securities decreased from ¥233.724 million in the same period of the previous year to none in the current quarter. In addition, the valuation difference on other securities increased from ¥755.290 million at the end of the previous fiscal year to ¥931.901 million. - FY2020WorsenedAnnual report
「Impairment loss on investment securities - 1,367,977」
An impairment loss on investment securities of ¥1,367.977 million was recorded in the current fiscal year. The valuation difference on other securities also decreased from ¥829.555 million to ¥755.290 million, with the valuation loss occurring alongside a narrowing valuation difference. - FY2020-Q3ReframedAnnual report
「Impairment loss on investment securities - 227,976」
An impairment loss on investment securities of ¥227.976 million was recorded, while the valuation difference on other securities increased from ¥829.555 million at the end of the previous fiscal year to ¥1,020.305 million. The valuation loss and recovery in valuation differences occurred concurrently. - FY2020-Q2WorsenedAnnual report
「Impairment loss on investment securities - 256,813」
An impairment loss on investment securities of ¥256.813 million was recorded as an extraordinary loss. In addition, the valuation difference on other securities decreased from ¥829.555 million at the end of the previous fiscal year to ¥696.341 million. - FY2020-Q1WorsenedAnnual report
「Impairment loss on investment securities - 233,724」
An impairment loss on investment securities of ¥233.724 million was recorded as an extraordinary loss, while the valuation difference on other securities decreased from ¥829.555 million at the end of the previous fiscal year to ¥773.981 million. - FY2019WorsenedAnnual report
「This was mainly due to a decrease in the valuation difference on other securities.」
The valuation difference on other securities decreased from ¥1,426 million at the end of the previous fiscal year to ¥829 million, and total net assets also decreased by ¥176 million. - FY2019-Q3WorsenedAnnual report
「Valuation difference on other securities 1,426,527 669,986」
The valuation difference on other securities decreased substantially from ¥1,426.527 million at the end of the previous consolidated fiscal year to ¥669.986 million, becoming a factor weighing on net assets and comprehensive income. - FY2019-Q2MitigatedAnnual report
「Valuation difference on other securities 1,426,527 1,750,473」
The valuation difference on other securities increased from ¥1,426.527 million at the end of the previous fiscal year to ¥1,750.473 million. In addition, no impairment loss on investment securities was recorded during the cumulative second-quarter period of the current consolidated fiscal year, while a gain on valuation of investment securities of ¥16.065 million was recorded. - FY2019-Q1MitigatedAnnual report
「Valuation difference on other securities 1,426,527 1,447,376」
The valuation difference on other securities increased from ¥1,426.527 million at the end of the previous fiscal year to ¥1,447.376 million. - FY2018MitigatedAnnual report
「Total net assets at the end of the current consolidated fiscal year amounted to ¥46,123 million, an increase of ¥939 million from the end of the previous consolidated fiscal year. This was mainly due to an increase in the valuation difference on other securities.」
The valuation difference on other securities increased from ¥1,085 million to ¥1,426 million, while the impairment loss on investment securities decreased from ¥4.870 million in the previous fiscal year to ¥273,000. - FY2018-Q3RestatedAnnual report
「Total net assets at the end of the third quarter of the current consolidated fiscal year amounted to ¥46,470 million, an increase of ¥1,285 million from the end of the previous consolidated fiscal year. This was mainly due to an increase in the valuation difference on other securities.」
The increase in the valuation difference on other securities continued to be indicated as a factor behind the increase in net assets. An impairment loss on investment securities of ¥111,000 was recorded. - FY2018-Q2ReframedAnnual report
「Total net assets at the end of the second quarter of the current consolidated fiscal year amounted to ¥45,905 million, an increase of ¥720 million from the end of the previous consolidated fiscal year. This was mainly due to an increase in the valuation difference on other securities.」
The increase in the valuation difference on other securities lifted net assets, while an impairment loss on investment securities of ¥111,000 was also recorded, indicating a recovery in valuation differences alongside a small valuation loss. - FY2018-Q1MitigatedAnnual report
「Total net assets at the end of the first quarter of the current consolidated fiscal year amounted to ¥45,456 million, an increase of ¥271 million from the end of the previous consolidated fiscal year. This was mainly due to an increase in the valuation difference on other securities.」
The valuation difference on other securities increased from ¥1,085.382 million to ¥1,271.969 million, and no impairment loss on investment securities was recorded in the current quarter. - FY2017-Q3MitigatedAnnual report
「This was mainly due to an increase in the valuation difference on other securities.」
The valuation difference on other securities amounted to ¥1,108.545 million, up from ¥752.117 million previously. In addition, the impairment loss on investment securities was ¥4.246 million, down from ¥6.216 million previously. - FY2017-Q2Partial recovery in valuation differencesAnnual report
「Impairment loss on investment securities 6,216」
An impairment loss on investment securities continued to be recorded, but decreased from ¥9.319 million previously to ¥6.216 million. In addition, the valuation difference on other securities recovered from ¥487.644 million previously to ¥752.117 million. - FY2017-Q1First statedAnnual report
「Impairment loss on investment securities ¥9.319 million」
The valuation difference on other securities narrowed from ¥837.467 million at the end of the previous consolidated fiscal year to ¥487.644 million, and an impairment loss on investment securities was recorded in the quarterly income statement.